Objectives 
Introduction

Previous studies have suggested possible cardio-protective effects of statin beyond lipid lowering. Several studies have demonstrated impact of the statin on left ventricular systolic function and prognosis in patients with heart failure (1-3). Moreover, a recent study has shown that statin may also improve the prognosis in patients with diastolic heart failure (4). Therefore, statin may have some favourable impact not only on left ventricular systolic function but also on left ventricular diastolic function. Although possible mechanisms affecting diastolic function have been suggested based on experimental data, to date the clinical impact of statin on left ventricular diastolic indices have not been well documented. This may be possibly because of the limitation of currently used Doppler-derived indices of left ventricular diastolic function such as the ratio of the early and late transmitral flow velocity (E/A) and the deceleration time of the E (DT), namely pre-load dependency and as a result presence of pseudonormal pattern appears. Recently, the ratio of the early transmitral filling velocity and the early dia-stolic mitral annular velocity, E/E', has been introduced as a relatively preload-independent non-invasive Doppler index (5-9).
Despite the previous data supporting the possible efficacy of statin on prognosis in patients with a known history of congestive heart failure, it is unknown whether or not statin also improves cardiac function and lowers the future risk of congestive heart failure in relatively low risk ischemic heart disease (IHD) patients without prior history of congestive heart failure (CHF) (Fig. 1) . Similarly, Kaplan-Meier plots of congestive heart failure-free survival curve showed a significantly higher survival rate in statin group than in no statin group (Fig. 2) T a b l e 4 . Cl i n i c a l E v e n t s d u r i n g F o l l o w-u p 
T a b l e 1 . Cl i n i c a l Ch a r a c t e r i s t i c s
T a b l e 2 . Me d i c a t i o n s T a b l e 3 . T wo -Di me n s i o n a l a n d Do p p l e r E c h o c a d i o g r a p h i c I n d i c e s significant. A p value < 0.05 was considered statistically significant. Statistical analysis was performed using commercially available software (Statview).
Results
Statin was used in 132 (31%) of 430 IHD patients (statin group). On the other hand, statin was not prescribed in the remaining 298 (69%) patients (no statin group
T a b l e 5 . Mu l t i v a r i a t e P r e d i c t o r s o f De a t h a n d Co n g e s t i v e He a r t F a i l u r e
F i g u r e 1 . Ka p l a n -Me i e r p l o t s o f c a r d i a c d e a t h -f r e e s u rv i v a l c u r v e s h o wi n g a s i g n i f i c a n t l y h i g h e r s u r v i v a l r a t e i n t h e s t a t i n g r o u p t h a n i n t h e n o s t a t i n g r o u p .
F i g u r e 2 . Ka p l a n -Me i e r p l o t s o f c o n g e s t i v e h e a r t f a i l u r ef r e e s u r v i v a l c u r v e s h o wi n g a s i g n i f i c a n t l y h i g h e r s u r v i v a l r a t e i n t h e s t a t i n g r o u p t h a n i n t h e n o s t a t i n g r o u p .
F i g u r e 3 . Ka p l a n -Me i e r p l o t s o f c a r d i a c e v e n t ( c a r d i a c d e a t h a n d c o n g e s t i v e h e a r t f a i l u r e ) -f r e e s u r v i v a l c u r v e s h o wi n g a s i g n i f i c a n t l y h i g h e r s u r v i v a l r a t e i n t h e s t a t i n g r o u p t h a n i n t h e n o s t a t i n g r o u p .
statin group (Fig. 3) .
Furthermore, Kaplan-Meier plots of cardiac event-free survival curves stratified by EF were also constructed (Fig. 4) . Both in patients with EF<50% and in patients with EF!50%, the event-free survival rate was significantly higher in statin group than in no statin group, suggesting that the favorable effect of statin was independent of cardiac systolic function.
A Fig. 6 .
quartile-dependent increase in the risk of cardiac death and congestive heart failure was seen with increasing plasma hsCRP but not with increasing LDL-cholesterol (Fig. 5). A quartile-dependent decrease in EF and increase in E/E' are shown in
Between the propensity-matched groups with and without statin, left ventricular systolic function (EF 59.2±10.4 vs. 59.0±10.7 %, p=NS) and diastolic functions (DT 219.2±60.7 vs. 213.7±57.8 msec, E/E' 12.6±5.1 vs. 13.6±5.3, both p= NS) (Fig. 7 ). Ka p l a n -Me i e r p l o t s o f c a r d i a c e v e n t -( c a r d i a c  d e a t h a n d c o n g e s t i v e h e a r t f a i l u r e ) f r e e s u r v i v a l c u r v e s h o wi n g a s i g n i f i c a n t l y h i g h e r s u r v i v a l r a t 
Discussion
Our study shows that statin may improve left ventricular
F i g u r e 4 . Ka p l a n -Me i e r p l o t s o f c a r d i a c e v e n t f r e e s u r v i v a l r a t e d u r i n g f o l l o w-u p i n p a t i e n t s wi t h ( A) e j e c t i o n f r a c t i o n ( E F ) < 5 0 % a n d ( B ) E F ≥ 5 0 %. T h e s t a t i n g r o u p h a d a s i g n i f i c a n t l y h i g h e r c a r d i a c e v e n t -f r e e s u r v i v a l r a t e d u r i n g f o l l o w-u p .
F i g u r e 5 . Ka p l a n -Me i e r c u r v e s f o r c a r d i a c e v e n t s b y q u a r t i l e s o f ( A) p l a s ma h s CRP a n d ( b ) L DL -c h o l e s t e r o l l e v e l .
F i g u r e 6 . A h s CRP q u a r t i l e -d e p e n d e n t d e c r e a s e i n E F ( A) a n d i n c r e a s e i n E / E ' ( B ) a r e o b s e r v e d .
systolic and diastolic function assessed by Doppler echocardiography including TDI analysis, which may be related to improved prognosis in low risk IHD patients without history of HF. These favorable effects of statin may in part be explained by its anti-inflammatory effect.
Statin and prognosis in IHD population
Several randomized trials have clearly demonstrated beneficial effects of statin on mortality and morbidity in IHD patients. Results of a randomized controlled trial have shown
e i n t h e s t a t i n g r o u p t h a n i n t h e p r o p e n s i t y s c o r e -ma t c h e d n o s t a t i n g r o u p . that fluvastatin significantly reduced major adverse cardiac events including cardiac death, non-fatal myocardial infarction or reintervention procedure following percutaneous coronary intervention (10). These favorable effects of statins come mainly from the lipid lowering effect and as a result an anti-atherosclerotic effect. In fact, intravascular ultrasound trials have demonstrated the impact of statins on suppressing coronary plaque progression (11
